Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients
出版年份 2017 全文链接
标题
Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients
作者
关键词
Adverse events, Physicians, Hemorrhage, Heart failure, Severe blood loss, Cancer treatment, Hypertension, Wound healing
出版物
PLoS One
Volume 12, Issue 11, Pages e0188943
出版商
Public Library of Science (PLoS)
发表日期
2017-12-01
DOI
10.1371/journal.pone.0188943
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- TheACVRL1c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients withENGmutations, but not in patients withACVRL1mutations
- (2015) Ludmila Pawlikowska et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART A
- Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials
- (2015) Wei-Xiang Qi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia
- (2015) Nicolas Azzopardi et al. mAbs
- Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia
- (2015) Quentin Maestraggi et al. MEDICINE
- Complications and mortality in hereditary hemorrhagic telangiectasia: A population-based study
- (2015) J. W. Donaldson et al. NEUROLOGY
- Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature
- (2015) Natalia P. Arizmendez et al. International Forum of Allergy & Rhinology
- Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia
- (2015) Daniela S. Ardelean et al. Frontiers in Genetics
- Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients
- (2014) Katherine M. Slusarz et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Bevacizumab Increases the Risk of Severe Congestive Heart Failure in Cancer Patients: An Up-to-Date Meta-Analysis with a Focus on Different Subgroups
- (2014) Wei-Xiang Qi et al. CLINICAL DRUG INVESTIGATION
- Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11)
- (2013) Jason Fangusaro et al. CANCER
- Correction: The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
- (2013) Limor Amit et al. PLoS One
- Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output
- (2012) Sophie Dupuis-Girod et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Hypoxia—a key regulator of angiogenesis and inflammation in rheumatoid arthritis
- (2012) Sofia Konisti et al. Nature Reviews Rheumatology
- The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment
- (2011) K.M.A.C. Luijten et al. AUTOIMMUNITY REVIEWS
- Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010
- (2011) Balvinder Rehal et al. PLoS One
- Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes
- (2010) F. A. B. Schutz et al. ANNALS OF ONCOLOGY
- Synovial tissue hypoxia and inflammation in vivo
- (2010) C. T. Ng et al. ANNALS OF THE RHEUMATIC DISEASES
- Treatment of bevacizumab-induced hypertension by amlodipine
- (2010) Olivier Mir et al. INVESTIGATIONAL NEW DRUGS
- A Review on Bevacizumab and Surgical Wound Healing
- (2009) Chad R. Gordon et al. ANNALS OF PLASTIC SURGERY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started